R&D Trends

Foundation Medicine, Agios collaborate on cancer metabolism programs

Friday, April 5, 2013 11:36 AM

Foundation Medicine, a molecular information company, and Agios Pharmaceuticals, a biopharmaceutical company, have formed a multi-year diagnostic partnership for Agios' lead programs in cancer metabolism.

More... »

Tetragenetics, Pfizer form collaboration in SionX technology

Wednesday, April 3, 2013 02:48 PM

Tetragenetics, a 2012 Gates Foundation phase II grant recipient and an emerging biotechnology company focused on particle-based vaccines and expression of ion channel drug targets, has entered into a collaboration agreement with an option for an exclusive license with Pfizer.

More... »

Aragen Bioscience, Innovent Biologics collaborate on biotherapeutic product development

Wednesday, April 3, 2013 01:46 PM

Aragen Bioscience, a privately held CRO, and Innovent Biologics, a privately held biopharmaceutical company, have initiated a collaboration for the development of manufacturing cell lines for biotherapeutic product development. Aragen Bioscience will develop robust CHO cell lines and assess critical product quality attributes for various antibodies and protein therapeutics. 

More... »

BRNI partners with Neurotrope BioScience to advance new Alzheimer's discoveries

Wednesday, April 3, 2013 12:14 PM

The Blanchette Rockefeller Neurosciences Institute (BRNI) at West Virginia University has entered into a strategic Joint Product Development and Commercialization Agreement with Neurotrope BioScience, a biotechnology company, in the field of neurodegenerative disease. The central focus of this collaboration will be to advance novel diagnostic and therapeutic technologies developed at BRNI that have shown exceptional promise in both preclinical and clinical models of Alzheimer's disease.

More... »

TheraVida, SK Chemicals to develop THVD-201 and THVD-202 for OAB, UUI

Wednesday, April 3, 2013 11:45 AM

TheraVida, a biopharmaceutical company based in Mountain View, Calif., and South Korea-based SK Chemicals have signed a license agreement for two of TheraVida's proprietary combination drug product candidates, THVD-201 and THVD-202. The agreement grants SK Chemicals exclusive rights to develop and commercialize THVD-201 and THVD-202 in South Korea for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI). 

More... »

European collaborative research project AgedBrainSYSBIO launches

Wednesday, April 3, 2013 09:20 AM

The AgedBrainSYSBIO project on systems biology of synapse proteins and aging was officially launched March 18 in Paris. The European collaborative research project is funded by the European Commission under the Health Work Program of the Seventh Framework Program.

More... »

Edison, Dainippon Sumitomo to develop orphan mitochondrial and adult CNS disease drugs

Friday, March 29, 2013 01:09 PM

Specialty pharmaceutical company Edison Pharmaceuticals has entered into a R&D and commercialization agreement with Dainippon Sumitomo Pharma, a Japanese pharmaceutical company, for the development of EPI-743 and EPI-589 in Japan.

More... »

GSK, Texas A&M to establish influenza vaccine facility in Texas

Friday, March 29, 2013 11:20 AM

The U.S. Department of Health and Human Services (DHHS) has approved GlaxoSmithKline’s (GSK) and The Texas A&M University System’s proposal to establish a $91 million influenza-vaccines manufacturing facility as the anchor of the Center for Innovation in Advanced Development and Manufacturing (CIADM) in Bryan-College Station, Texas.

More... »

BioDelivery Sciences acquires topical clonidine gel for painful diabetic neuropathy

Wednesday, March 27, 2013 11:53 AM

BioDelivery Sciences International (BDSI) has entered into a worldwide licensing agreement with privately held Arcion Therapeutics, where BDSI will develop and commercialize topical clonidine gel (formerly ARC4558) for the treatment of painful diabetic neuropathy (PDN) and potentially other indications. 

More... »

Lundbeck, Otsuka expand alliance, plan to development Lu AE58054 for Alzheimer's

Wednesday, March 27, 2013 11:24 AM

Global pharmaceutical company H. Lundbeck and global healthcare company Otsuka Pharmaceutical have formed a license and development agreement for Lu AE58054, a selective 5HT6 receptor antagonist currently in development for the treatment of Alzheimer's disease.

More... »